PDCD1 and metastatic melanoma: Four recent clinical trials, two conducted in Israel, one in the United States, and the other in Canada [18-21], suggest that fecal microbiota transplant (FMT) may restore sensitivity to anti-PD-1 inhibition in immunotherapy-resistant metastatic melanoma.